Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

264.49 +0.49 (+0.19%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,520,595
Open 262.48
Bid (Size) 263.06 (1)
Ask (Size) 264.55 (1)
Prev. Close 264.00
Today's Range 261.36 - 264.55
52wk Range 253.30 - 346.85
Shares Outstanding N/A
Dividend Yield 3.40%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
Spotlight on Amgen: Analyzing the Surge in Options Activity
Via Benzinga

Performance

YTD
-11.06%
-11.06%
1 Month
-10.04%
-10.04%
3 Month
-20.07%
-20.07%
6 Month
-17.17%
-17.17%
1 Year
-6.84%
-6.84%

More News

Read More
2 Excellent Dividend Stocks to Buy on the Dip
Via The Motley Fool
What's Going On With Amgen Stock On Friday?
Via Benzinga
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
Via Investor's Business Daily
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Via Investor's Business Daily
Unpacking the Latest Options Trading Trends in Amgen
Via Benzinga
Demystifying Amgen: Insights From 13 Analyst Reviews
Via Benzinga
Is Amgen Still a Top Dividend Stock?
Via The Motley Fool
10 Biggest Losers of The Dow Jones Index's 10-Day Losing Streak
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
Via Investor's Business Daily
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
Via Investor's Business Daily
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
MarketBeat Week in Review – 12/2 - 12/6
Via MarketBeat
Topics Economy Government Immigration
Exposures Economy Immigration Interest Rates
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Via MarketBeat
13 Healthcare Sector Stocks With Healthy Valuation
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Via The Motley Fool
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.